Boston Family Office LLC Sells 3,046 Shares of Novo Nordisk A/S (NVO)

Boston Family Office LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,809 shares of the company’s stock after selling 3,046 shares during the quarter. Boston Family Office LLC’s holdings in Novo Nordisk A/S were worth $2,566,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. Fisher Asset Management LLC grew its holdings in shares of Novo Nordisk A/S by 4.8% during the 4th quarter. Fisher Asset Management LLC now owns 12,705,477 shares of the company’s stock worth $681,903,000 after purchasing an additional 580,753 shares in the last quarter. Folketrygdfondet grew its holdings in shares of Novo Nordisk A/S by 4.4% during the 3rd quarter. Folketrygdfondet now owns 7,217,043 shares of the company’s stock worth $347,501,000 after purchasing an additional 302,851 shares in the last quarter. Saratoga Research & Investment Management grew its holdings in shares of Novo Nordisk A/S by 1.0% during the 4th quarter. Saratoga Research & Investment Management now owns 1,510,356 shares of the company’s stock worth $81,061,000 after purchasing an additional 14,800 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of Novo Nordisk A/S by 9.9% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,436,778 shares of the company’s stock worth $69,181,000 after purchasing an additional 129,364 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in shares of Novo Nordisk A/S by 16.3% during the 3rd quarter. Canada Pension Plan Investment Board now owns 978,800 shares of the company’s stock worth $47,129,000 after purchasing an additional 137,300 shares in the last quarter. 6.19% of the stock is currently owned by institutional investors.

Novo Nordisk A/S (NYSE NVO) opened at $48.52 on Friday. The company has a market capitalization of $96,380.00, a P/E ratio of 19.18, a P/E/G ratio of 3.20 and a beta of 0.57. Novo Nordisk A/S has a 52-week low of $32.89 and a 52-week high of $58.37.

The business also recently announced a special dividend, which will be paid on Tuesday, April 3rd. Investors of record on Monday, March 26th will be given a dividend of $0.8117 per share. The ex-dividend date of this dividend is Friday, March 23rd. This represents a dividend yield of 0.96%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 32.41%.

Novo Nordisk A/S declared that its board has approved a stock buyback program on Thursday, February 1st that authorizes the company to buyback shares. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Several equities analysts recently commented on the company. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Friday, January 26th. Morgan Stanley upgraded Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Friday, December 1st. Deutsche Bank restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Monday, January 8th. Bank of America upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Finally, JPMorgan Chase & Co. upgraded Novo Nordisk A/S from an “underweight” rating to a “neutral” rating in a research report on Friday, December 29th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $64.00.

TRADEMARK VIOLATION WARNING: “Boston Family Office LLC Sells 3,046 Shares of Novo Nordisk A/S (NVO)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://sportsperspectives.com/2018/02/09/boston-family-office-llc-sells-3046-shares-of-novo-nordisk-a-s-nvo.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply